Parataxis, Bridge Biotherapeutics Ink Deal to List Bitcoin Treasury Firm on Korea's KOSDAQ

Published on 20/06/2025 at 16:19

Reuters

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Bridge Biotherapeutics, Inc.

Bridge Biotherapeutics, Inc. announced that it has received KRW 25.000000416 billion in funding from Parataxis Holdings LLC	01/07	CI
Parataxis Korea Fund I Llc managed by Parataxis Holdings LLC acquired 36.98% stake in Bridge Biotherapeutics, Inc. from Kim Byung, Jung Jung Lee, Jungsoon Lee, Lim Jong-jin, Lee Bok-kyu and others	30/06	CI
Parataxis, Bridge Biotherapeutics Ink Deal to List Bitcoin Treasury Firm on Korea's KOSDAQ	20/06	RE
Bridge Biotherapeutics, Inc. announced that it expects to receive KRW 25.000000416 billion in funding from Parataxis Holdings LLC	20/06	CI
Parataxis Korea Fund I Llc and Parataxis Holdings LLC entered into a definitive agreement to acquire 36.98% stake in Bridge Biotherapeutics, Inc. from Kim Byung, Jung Jung Lee, Jungsoon Lee, Lim Jong-jin, Lee Bok-kyu and others for KRW 25 billion.	20/06	CI
Bridge Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	14/05	CI
Bridge Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	21/03	CI
Bridge Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	14/11	CI
Bridge Biotherapeutics and HitGen Inc. Initiate Research Collaboration to Advance Novel Cancer Therapeutics Program	22/24/22	CI
Bridge Biotherapeutics Announces Completion of Enrollment in the Phase 2a Clinical Study of BBT-877 for the Treatment of Idiopathic Pulmonary Fibrosis	30/24/30	CI
Bridge Biotherapeutics Launches Research Collaboration with Emory University School of Medicine to Explore Combination Therapy of BBT-877 for KRAS/P53 Mutant NSCLC Patients Resistant to Anti-PD-1 Blockade	29/24/29	CI
Bridge Biotherapeutics Announces Research Collaboration with the University of Colorado School of Medicine to Explore Potential of BBT-877 for Immuno-Oncology	27/24/27	CI
Bridge Biotherapeutics, Inc. announced that it has received KRW 1.99999872 billion in funding	22/24/22	CI
Bridge Biotherapeutics, Inc. announced that it expects to receive KRW 1.99999872 billion in funding	12/24/12	CI
Gpcr Therapeutics, Inc. Collaborates with Bridge Biotherapeutics, Inc. to Pursue Joint Development and Commercialization of the Combination Therapy	14/23/14	CI
Bridge Biotherapeutics Announces Initiation of Phase 1/2 Clinical Trial of BBT-207 in EGFR-Mutant NSCLC	31/23/31	CI
Bridge Biotherapeutics Announces Positive Recommendation from the Independent Data Monitoring Committee of the BBT-877 Phase 2a Study in Idiopathic Pulmonary Fibrosis	26/23/26	CI
Bridge Biotherapeutics, Inc.(KOSDAQ:A288330) dropped from S&P Global BMI Index	18/23/18	CI
Bridge Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/23/12	CI
Bridge Biotherapeutics Inc. Releases Updated Preclinical Data for BBT-207 at the AACR Annual Meeting	19/23/19	CI
Bridge Biotherapeutics Announces First Patient Dosed in its Phase 2a Clinical Trial of BBT-877, a Potent Autotaxin Inhibitor for the Treatment of Idiopathic Pulmonary Fibrosis	13/23/13	CI
Bridge Biotherapeutics Presents Phase 2A Clinical Trial Results for BBT-401	21/23/21	CI
Bridge Biotherapeutics, Inc. Initiates Phase 2 Clinical Trial of BBT-877 in Patients with Idiopathic Pulmonary Fibrosis	08/22/08	CI
Bridge Biotherapeutics, Inc. Presents Non-Clinical Study Results for 2 IPF Candidates at the IPF Summit 2022	02/22/02	CI
Bridge Biotherapeutics Receives FDA Authorization to Proceed with Phase 2 Study of BBT-877	16/22/16	CI